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Background: Pancreatic enzyme replacement therapy (PERT) is critical for correction of exocrine pancreatic insufficiency (EPI) in patients with
cystic fibrosis (CF).
Methods: This was a randomized, placebo-controlled PERT withdrawal study evaluating the efficacy and safety of PANCREAZE® (pancrelipase)
in CF patients with EPI. Participants (n=49) entered an open-label, ≤14 day run-in phase, maintained a high-fat diet (100±15 g/day), and
received PANCREAZE® (10.5 or 21). Participants with a coefficient of fat absorption (CFA)≥80% (n=40) were then randomized (1:1) to
receive either PANCREAZE® or placebo during a double-blind, ≤7 day withdrawal phase.
Results: PANCREAZE® improved fat absorption as shown by significantly lower mean±SD change in CFA between open-label and double-blind
phases for PANCREAZE® (−1.5±5.88%; pb0.001) compared to placebo (−34.1±23.03%). Protein absorption was similarly improved. No
unexpected adverse events were reported.
Conclusions: This study demonstrated PANCREAZE® was effective in treating EPI due to CF and was safe and well tolerated.
© 2011 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Coefficient of fat absorption; Cystic fibrosis; Exocrine pancreatic insufficiency; Pancreatic enzyme replacement therapy; Pancrelipase; PANCREAZE®1. Introduction
Approximately 85 to 90%of cystic fibrosis (CF) patients suffer
from pancreatic duct obstruction associated exocrine pancreatic☆ Prior Presentation: Previously presented at the annual meeting of the (a) North
American Society for Pediatric Gastroenterology, Hepatology, and Nutrition,
November 2009, National Harbor, MD, and (b) North American CF Conference,
October 2009, Minneapolis, MN, USA.
⁎ Corresponding author at: Cincinnati Children's Hospital Medical Center,
CCRF, Room 4029, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA.
Tel.: +1 513 636 6361; fax: +1 513 636 3723.
E-mail address: Bruce.Trapnell@cchmc.org (B.C. Trapnell).
1569-1993/$ - see front matter © 2011 Published by Elsevier B.V. on behalf of Eu
doi:10.1016/j.jcf.2011.04.005insufficiency (EPI) [1]. The resultant enzyme deficiency causes
malabsorption resulting in gastrointestinal symptoms, failure to
thrive in infants, poor growth in children, andweight loss in adults
[2]. Pancreatic enzyme replacement therapy (PERT) is the
treatment of choice for EPI in CF patients and is critical to
prevent malabsorption and maintain an optimal nutritional status
[3]. PERT is considered effective and well tolerated based on
clinical experience and well-controlled clinical trials [3–6].
Reports of fibrosing colonopathy associated with use of high
doses of some enzyme supplements [7] and lower efficacy of
some generic PERT preparations [8] prompted the United States
Food and Drug Administration (US FDA) to evaluate the need forropean Cystic Fibrosis Society.
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of pancreatic enzymes. Due to inconsistencies in formulation,
activity, stability, and bioavailability of pancreatic enzyme
preparations, the US FDA issued a requirement in 2004 that
manufacturers of pancreatic enzyme supplements must file a New
DrugApplication (NDA) to ensure consistent efficacy, safety, and
quality of these agents [9].
PANCREAZE® (pancrelipase) [10] is a PERT prescribed for
use in infants, children, and adults for treatment of steatorrhea,
secondary to EPI in CF or chronic alcoholic pancreatitis since
1988. The present study was conducted to reaffirm the efficacy
and safety of PANCREAZE® in order to fulfill the US FDA
requirements to submit an NDA for registration of the product.
The primary objective of this randomized, double-blind, placebo-
controlled, withdrawal study was to evaluate the efficacy of
PANCREAZE® capsules on the quantitative change in fat
absorption in pediatric, adolescent and adult patients with CF
associated clinical symptoms of EPI. Secondary objectives
included evaluation of effect of PANCREAZE® capsules on
the quantitative change in protein absorption and improvement in
clinical signs and symptoms of EPI in these patients. The safety of
PANCREAZE® in this patient population was also assessed.
2. Methods
2.1. Study drug
PANCREAZE® 10.5 and 21 capsules are oral pancreatic
enzyme supplements containing enteric coated microtablets of
enzymes extracted from porcine pancreas. PANCREAZE® 10.5
capsules contain 10,500, 25,000, and 43,750 USP units of
lipase, protease, and amylase respectively. PANCREAZE® 21
capsules contain 21,000, 37,000, and 61,000 USP units of
lipase, protease, and amylase respectively.
2.2. Study population
Males and females aged 7 to 60 years were eligible if they had
a diagnosis of CF confirmed by genotype analysis or sweat test
(chloride levels N60 mmol/L), and CF-related EPI confirmed by
documentation of an abnormal coefficient of fat absorption
(CFA), or by a fecal elastase test (b100 μg fecal elastase/gram
stool)≤3 months of screening or a fecal elastase test during
screening. Participants were on a stable diet and a PERT that
adequately controlled EPI symptoms, and had received stable
doses of any medications affecting the gastrointestinal tract
for≥1 month before screening. A CFA≥80% during the 72-
hour stool collection period was required for randomization and
inclusion in the double-blind phase.
Participants were excluded for: extreme cachexia (b10th
percentile of body mass index); severe/acute pulmonary disease
unrelated to complications of cystic fibrosis; exacerbation of CF
pulmonary disease≤1 month before screening; congenital
anomalies of gastrointestinal tract; distal intestinal obstruction
syndrome≤6 months of screening or requirement of surgical
management to treat; hypersensitivity to porcine products;
clinically significant gastrointestinal symptoms (e.g., vomiting,constipation); or disease or disorder that could interfere with
assessment of study drug. Participants were excluded if they
were taking drugs affecting blood uric acid concentrations or
prokinetic agents (e.g., metoclopramide, cisapride,)≤30 days of
screening; concurrent supplemental enteral nutrition; immuno-
suppressant agents for organ transplantation; or systemic steroid
therapy. Females were excluded if pregnant, planning to become
pregnant, or nursing.
Use of other pancreatic enzyme preparations, mineral oil,
magnesium, polyethylene glycol, and potassium supplementation
was prohibited, as were agents affecting gastrointestinal motility
(except a single dose of bisacodyl 10 mgduring an inpatient visit).
Stable use of other gastrointestinal medications was allowed.
Recurrent antibiotic therapy was allowed if a stable dose had been
administered for≥1 month before screening.
The Independent Ethics Committee or Institutional Review
Board at each study site approved the protocol. The study was
conducted in accordance with Good Clinical Practices, the
Declaration of Helsinki, all applicable regulatory requirements,
and with the protocol. All participants or their legal represen-
tatives provided written informed consent.
2.3. Study design
The study was conducted from July 2008 to February 2009 at
11 centers in the United States and 1 center in Canada. The study
consisted of a 7-day screening phase,≤14-day open-label run-in
phase, and≤7-day placebo-controlled, double-blind, withdrawal
phase. The duration of the double-blind phase ranged from 4 to
7 days, depending on patients’ gastrointestinal transit time.
During the screening phase and after completion of laboratory
assessments, participants’ current PERT was discontinued, a
high-fat diet (100±15 g fat/day or 3 g/kg/day) was initiated, and
PANCREAZE® was administered based on the patient's lipase
requirement during the previous 3 days. The number of
PANCREAZE® (10.5 or 21) capsules administered was adjusted
to optimize digestion of the high-fat diet based on clinical signs
and symptoms according to CF Foundation PERT recommenda-
tions, to a maximum of 10,000 units of lipase/kg/day [11].
The PANCREAZE®dosewas stabilized during screening (or, if
not, within the first 72 h of the open-label phase) andmaintained for
≥48 h. An initial inpatient, 72-hour stool collection was performed
to measure CFA. Stool collection periods were marked by oral
administration of a stool marker (FD&C blue dye, two 250 mg
capsules) on the first day of the collection period and 72 h±1 h
after taking the first dyemarker. The collection period startedwith
the first stool showing presence of bluemarker and endedwith the
first blue stool following ingestion of the second stool marker.
Stool samples were preserved at −20 °C and sent to a central
laboratory for analysis of fecal fat and nitrogen content. End-of-
study assessments were performed after the stool collection
period or upon early withdrawal from the double-blind phase.
During the double-blind phase, participantswith a CFA≥80%
were randomized (1:1) to continue their optimized dose of
PANCREAZE® (10.5 or 21) or switched to placebo. A computer-
generated randomization schedule achieved balancing, using
randomly-permuted treatment blocks. After ≥1 day of double-
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as described above.
2.4. Efficacy assessments
The primary efficacy endpoint was change in percent CFA
between the 72-hour stool collections at the end of the open-label
phase and double-blind phase. Fat intake (dietary fat) and fat
excretion (fecal fat) data were used to calculate fecal fat excretion
per 24 h,whichwas determined from the 72-hour stool collection.
Percent CFA was calculated as: Percent CFA={[Fat intake
(grams)−Fat excretion (grams)] /Fat intake (grams)}×100.
A key secondary variablewas change in coefficient of nitrogen
absorption (CNA), a surrogate for protein absorption, from the
open-label phase to the double-blind phase. The ingested nitrogen
was determined from diet records, and nitrogen excretion
measurements comprised total nitrogen (fecal, in grams) for
each 72-hour stool collection period. Percent CNAwas calculated
as: Percent CNA={[nitrogen intake (grams)−nitrogen excretion
(grams)] /nitrogen intake (grams)}×100.
Another key secondary variable was prevention of the clinical
signs and symptoms of EPI (abdominal pain, bloating, diarrhea,
greasy stools, vomiting) during the double-blind phase. Overall
improvement in health from the open-label phase to the double-
blind phase was assessed using a self-reported global assessment
of change (GAC) scale (0=worse, 1=same, 2=better, and
3=excellent).
Participants (or parent/legal guardian) maintained a daily record
of their diet (nutrition diary), study drug taken (PANCREAZE® or
placebo), and EPI symptoms and signs. Number of stools and their
consistency and appearance (1=hard, 2=formed/normal, 3=soft,
4=watery or oily/greasy) was recorded in a stool diary. There was
daily telephone contact with participants to monitor recording of
information and clinical signs and symptoms.
2.5. Safety assessments
Treatment-emergent adverse events (TEAEs) were moni-
tored throughout the study. Vital signs, physical examinations,
and clinical laboratory tests (hematology, blood chemistry, and
urinalysis) were performed at screening and end of study.
2.6. Statistical analysis
Sample size was determined based on the primary efficacy
variable. With 18 participants per group, the study had 90%
power to detect a treatment difference of 31.2% (SD 22.6%) in
CFA using a 2-sided t-test at significance level of 0.05. A sample
size of 20 participants per group was selected to accommodate a
10% dropout rate. Numeric data are presented as mean±standard
deviation unless indicated otherwise. Efficacy analyses included
all randomized participants (intent-to-treat analysis set). The last-
observation-carried-forward approach was used to impute
missing data for the intent-to-treat analysis. Safety analyses
included randomized participants who received≥1 dose of study
drug and contributed safety data after start of treatment.The change in CFA and CNA from open-label to double-blind
was analyzed using an analysis-of-covariance (ANCOVA) model
with treatment as a factor and baseline values as covariates. Fisher's
exact test was performed to assess ad-hoc comparisons to compare
number of patients reporting abnormal stool consistency between
groups. Results of clinical symptoms of EPI, stool diary, and safety
assessments were summarized using descriptive statistics.
3. Results
3.1. Patient disposition, baseline characteristics and study flow
Of 48 participants entering the open-label PERT phase, those
with a CFAN80% (n=40) were randomized to either continue
receiving PANCREAZE® (n=20) or switch to placebo (n=20)
during the double-blind phase.All randomized participants in both
groups completed the study and were included in the efficacy and
safety analyses (Fig. 1).
Baseline and demographic characteristics were similar for
PANCREAZE® and placebo groups (Table 1). The baseline CFA
was89.4±4.88% and similar in both groups. The duration of study
drug exposure in the open-label phase was 12.3±3.74 days and
during the double-blind phase was 5.1±0.72 and 5.4±0.81 days
for PANCREAZE® and placebo groups, respectively.
The PERT dose was 6274.4±2443.7 units/kg/day during the
open-label phase and 6403.2±2671.4 units/kg/day in the
PANCREAZE® group during double-blind phase. Concomitant
medications used by participants in the PANCREAZE® and
placebo groups included proton pump inhibitors (n=12, 60%;
n=10, 50%) and H2-receptor antagonists (n=1, 5%; n=5, 25%;
respectively).
3.2. Efficacy
The mean CFA was similar in PANCREAZE® and placebo
groups at baseline (Table 1) but was markedly higher in the
PANCREAZE® group than the placebo group in the double-
blind withdrawal phase (Table 2). The CFA between open-label
and double-blind phases (primary endpoint) was similar for the
PANCREAZE® group but was markedly lower in the placebo
group (Table 2). The change in CFA for individual participants
ranged from +8% to −16% in the PANCREAZE® group and
from 0% to −75% in the placebo group (Fig. 2A). The primary
endpoint results were similar for pediatric and adult patients
(Table 2).
The CNA, a key secondary outcome was also similar in
PANCREAZE® and placebo groups at baseline (Table 1) but was
markedly higher in the PANCREAZE® group than the placebo
group in the double-blindwithdrawal phase (Table 2). The change
in CNA between open-label and double-blind phases was not
different for the PANCREAZE® group but was markedly lower
in the placebo group (Table 2). The change in CNA for individual
participants ranged from +9% to −7% in the PANCREAZE®
group and from −3% to −62% in the placebo group (Fig. 2B).
The number of participants reporting≥1 EPI-related symptom
during the double-blind phase was less in the PANCREAZE®
group than in the placebo group (Table 3). Abdominal pain was
Screening 
n=54 
Enrolled 
n=49 
Screen failures (n=5)
(n=3) 
• Uncontrolled steatorrhea while 
receiving PERT (n=1) 
• Compromising medical condition (n=1) 
Randomized 
n=40 
Not randomized (n=8)
•Adverse events (n=1) 
•Noncompliance with study drug (n=1) 
•Withdrew consent (n=1) 
•CFA 80% in open-label or CFA 
information not available (n=5) 
Placebo 
n=20 
PANCREAZE ®
n=20
Completed 
n=20 
Analyzed for 
efficacy and safety 
n=20 
Completed 
n=20 
Analyzed for 
efficacy and safety 
n=20 
Open-label phase 
 n=48 
Withdrew consent (n=1)
Fig. 1. Disposition of the study participants. PERT, pancreatic enzyme replacement therapy; CFA, coefficient of fat absorption.
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versus n=6 (30%)).
The median stool consistency score was 2.0 in both groups at
baseline, and was relatively unchanged at 2.0 in PANCREAZE®
group and worsened to 2.9 in the placebo group during the
double-blind phase. The number of participants reporting
abnormal stool consistency during the double-blind phase was
less in the PANCREAZE® compared to placebo groups, and
fewer participants reported watery/greasy stools in the PAN-
CREAZE® group than in the placebo group (Table 3). At study
completion, participants in the PANCREAZE® group reported
higher GAC scores than did those in the placebo group (Table 3).
3.3. Safety
During the open-label phase, 15 (38%) participants reported
at least 1 TEAE. For 10 (25%) participants, the TEAEs were
considered by the investigator to be related to study medication.
Upper abdominal pain and constipation were the most common
TEAEs and each was reported in 3 (8%) participants.
PANCREAZE® 10.5 was discontinued in one participant whodeveloped abdominal pain judged by the investigator to be
unrelated to PANCREAZE®.
During the double-blind phase, the overall incidence of
TEAEs was lower in PANCREAZE® group than in placebo
group (Table 3). The TEAEs were considered by the investigator
to be related to study medication in 4 (20%) participants on
PANCREAZE® and 10 (50%) on placebo. The most common
events were gastrointestinal symptoms (abdominal pain, diarrhea,
increased flatulence, abnormal stools), all of which were reported
less frequently in participants receiving PANCREAZE® than
placebo.No instances of discontinuing studymedication occurred
during the double-blind phase.
No serious adverse eventswere reported and no deaths occurred
during the study. No clinically relevant changes in laboratory
values or vital signs were observed.
4. Discussion
This study demonstrated that PANCREAZE® was an
effective, well tolerated, and safe therapy for maldigestion and
malabsorption caused by EPI in CF patients and reaffirmed prior
Table 1
Baseline characteristics of randomized participants.
Placebo
(N=20)
PANCREAZE®
(N=20)
Total
(N=40)
Age, years
Mean (SD) 23 (11.6) 24 (13.4) 23.7 (12.4)
Age category, n (%)
Pediatric (7 to b18 years) 8 (40) 6 (30) 14 (35)
Adult (18 to 60 years) 12 (60) 14 (70) 26 (65)
Gender, n (%)
Male 13 (65) 9 (45) 22 (55)
Female 7 (35) 11 (55) 18 (45)
Race, n (%)
White 19 (95) 17 (85) 36 (90)
Black or African American 1 (5) 1 (5) 2 (5)
Other or unknown 0 (0) 2 (10) 2 (6)
Weight (kg), Mean (SD) 59.6 (17.1) 56 (15.2) 57.8 (16.0)
Fat and nitrogen absorption
% CFA, Mean (SD) a 90.5 (4.5) 88.2 (5.1) 89.4 (4.9)
% CNA, Mean (SD) a 84.5 (7.8) 81.2 (6.4) 82.8 (7.2)
SD: standard deviation; CFA: coefficient of fat absorption; CNA: coefficient of nitrogen absorption.
a Last measurement before the first dose in the open-label phase.
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CFA, CNA and stool consistency and reduced EPI-related
symptoms in CF patients with EPI. No new safety concerns were
associated with PANCREAZE® treatment.
Both the magnitude of the CFA achieved in patients taking
PANCREAZE® and the significant difference in the mean CFA
between PANCREAZE® and placebo groups observed in our
study provide strong evidence of the efficacy of PANCREAZE® as
therapy of EPI in CF patients. CFA is considered the ‘gold
standard’ for evaluating the efficacy of a PERT for EPI [16]. These
CFA results were supported by similar findings with the less
commonly used parameter, CNA, as well as the improvement in
GCI, and reduction in the frequency of symptoms in patients taking
PANCREAZE® compared to placebo. The magnitude of the
difference between groups in some of the symptoms and stool
scores were relatively small which may reflect the short duration of
treatment. The clinical outcome measures we used have been used
successfully, and with similar results, in other PERT studies in CF
patients and thus provide further support for our findings [3–6].
An important finding of the study is that no serious adverse
events occurred and no new safety signal was observed forTable 2
Primary and key secondary efficacy assessments of the participants.
Endpoint/
group
End of study
Placebo PANCREAZE®
% CFA, mean (SD)
All patients 56.4 (24.93) 86.8 (8.09)
Adult 51.5 (25.47) 86.6 (9.38)
Pediatric 63.6 (23.81) 87.1 (4.46)
% CNA, mean (SD)
All patients 57.9 (19.73) 82.4 (6.00)
Adult 54.6 (19.18) 82.8 (6.73)
Pediatric 63.0 (20.76) 81.6 (4.21)
CFA: coefficient of fat absorption; CNA: coefficient of nitrogen absorption. Intent-to-
PANCREAZE® (14 adults; 6 children); The change in CFA and CNA from open-l
treatment as a factor and baseline values as covariates.PANCREAZE®.As expected in patients with EPI, adverse events
were mostly gastrointestinal in origin. Importantly, the overall
safety profile was similar in adults and children. Direct
comparison of our results to those other PERT studies is hampered
by differences among studies including the formulation of drug
evaluated (Creon; EUR-1008; Pancreatin), dose of pancrelipase
tested (10,000 lipase units/kg/day vs. 4000 lipase units/g of fat),
study design used (e.g., withdrawal design vs. crossover design),
treatment duration (5 vs. 7 days), and participant age (7–60 vs. 7–
11/≥12 years) [3–6]. However, the overall pattern of adverse
events observed for PANCREAZE® appears consistent with other
PERT studies.
Results demonstrated the efficacy and safety of PAN-
CREAZE® as therapy of EPI in both pediatric and adult CF
patients. While this may be expected given that the pathophys-
iology of EPI and treatment effects of PERT are similar in
infants, children, adolescents and adults [1], it is important that
both the primary endpoint results and safety profile were similar
in individual pediatric and adult patients. Notwithstanding,
potential dietary, tolerability, and efficacy differences may exist
between pediatric and adult patients based on the impact ofChange from baseline P value
Placebo PANCREAZE®
−34.1 (23.03) −1.5 (5.88) b0.001
−38.2 (24.42) −1.2 (5.87) b0.001
−28.1 (20.78) −2.0 (6.40) 0.008
−26.5 (15.30) 1.3 (4.71) b0.001
−26.8 (15.02) 2.2 (4.11) b0.001
−26.2 (16.74) −0.8 (5.72) 0.002
treat analyses set with 20 participants in Placebo (12 adults; 8 children), and 20 in
abel to double-blind was analyzed using an analysis-of-covariance model with
Fig. 2. Individual participant data for (A) change in coefficient of fat absorption
(CFA) and (B) change in coefficient of nitrogen absorption (CNA) between the open-
label phase and double-blind phase for placebo (n=20) or PANCREAZE® (n=20).
Table 3
Other secondary efficacy and safety assessments of the participants.
Assessment, n (%) Treatment group
Placebo (N=20) Placebo (N=20)
n (%) n (%)
EPI symptoms a
Any 11 (55) 4 (20)
Abdominal pain 6 (30) 3 (15)
Bloating 3 (15) 1 (5)
Diarrhea 4 (20) 0 (0)
Greasy stools 3 (15) 0 (0)
Vomiting 0 (0) 1 (5)
Stool category b
Abnormal stool 18 (90) 15 (75)
Hard 0 (0) 4 (20)
Soft 16 (80) 13 (65)
Watery or greasy 14 (70) 2 (10)
GAC score c
Excellent 0 (0) 4 (20)
Better 2 (10) 9 (45)
Same 11 (55) 7 (35)
Worse 7 (35) 0 (0)
Treatment-emergent adverse events
Any TEAE 12 (60) 8 (40)
Treatment-related TEAE 10 (50) 4 (20)
Most common TEAE d
Diarrhea 4 (20) 0 (0)
Abdominal pain 3 (15) 2 (10)
Abdominal pain upper 3 (15) 1 (5)
Flatulence 3 (15) 1 (5)
Abnormal feces 3 (15) 0 (0)
Fatigue 2 (10) 0 (0)
EPI: exocrine pancreatic insufficiency; GAC: global assessment of change;
TEAE: treatment-emergent adverse event.
a Number (percent) of patients with≥1 EPI symptom during treatment.
b Reported at least one during treatment; hard, soft and watery or oily
considered abnormal.
c Response at end of study.
d Occurring in≥2 participants (≥10%) in either treatment group.
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effector of efficacy measurements [2,17,18]. In this study, the
comparison of two age groups was based on small sample size
and a larger sample size may be required to detect more subtle
differences.
The design of our study (i.e., randomized withdrawal) was
strongly influenced by the ethical consideration of minimizing
exposure of CF patients to placebo since it is well-established
that PERT is critical to the well-being of these patients. The
screening and open-label treatment period permitted stabiliza-
tion of PERT dosing before beginning the baseline stool
collection and minimizing the time on placebo. While the
relatively short duration of treatment did not address the long-
term efficacy and tolerability of PANCREAZE®, the safety
profile has been demonstrated through years of established
clinical use in CF patients.
The doses of PANCREAZE® tested (10.5 and 21)
permitted optimal management of EPI in adult and pediatric
patients on a high-fat diet without tolerability or safety issues
based on PANCREAZE® product dosing recommendations.
PANCREAZE® treatment was adjusted to accommodate a
high-fat target diet and to optimize digestion based on clinical
signs and symptoms within the CF Foundation recommenda-
tions for PERT up to a maximum of 10,000 units lipase/kg/day
[12]. The average daily dose of lipase administered during the
open-label and double-blind phases (6274 and 6403 units/kg/
day, respectively) was within the range of doses utilized inother studies [4–6]. The dose used in this study potentially
limits generalization of the recommendations that can be made
with regard to treatment of CF patients requiring other (lesser)
doses.
These results provide strong evidence of the efficacy and
safety of PANCREAZE® therapy of EPI in pediatric and adult
patients when administered according to CF Foundation
recommendations for PERT. The US FDA recently approved
PANCREAZE® as therapy of EPI in CF and other conditions.
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